{"product_id":"enovis-marketing-mix","title":"Enovis Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Enovis’s product design, pricing architecture, distribution channels, and promotional tactics combine to drive growth and clinical adoption; the preview teases insights, but the full 4P’s Marketing Mix delivers detailed, editable strategy, data-driven examples, and slide-ready content—perfect for consultants, students, and executives seeking immediate, actionable intelligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReconstructive Orthopedic Implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnovis’ reconstructive orthopedic implants include hip, knee, and shoulder systems engineered with advanced alloys and anatomic geometries to cut wear and raise mobility; implant sales contributed to Enovis’ $1.4B orthopedic revenue in FY2024, up 11% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBracing and Support Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnovis’s DonJoy brand anchors its bracing and support portfolio, delivering rigid and soft braces that drove roughly $320 million in orthopedics sales in FY2024 and sustain a market-leading share in sports medicine and post-op care.\u003c\/p\u003e\n\u003cp\u003eProducts serve pro athletes and everyday patients, reducing re-injury rates by up to 30% in published rehab studies and improving patient-reported stability and pain scores.\u003c\/p\u003e\n\u003cp\u003eOngoing R\u0026amp;D in lightweight composites and ergonomic fit—backed by 12 US patents as of 2025—keeps DonJoy supports the industry benchmark for performance and comfort.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Robotics and Guidance Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe ARVIS augmented reality system shows Enovis’s push into high-tech surgical care by giving surgeons real-time visual guidance during procedures, improving implant placement precision and workflow efficiency.\u003c\/p\u003e\n\u003cp\u003eAs a wearable (not a bulky cart), ARVIS cuts OR footprint and, per Enovis 2024 disclosures, aims to lower revision rates—studies suggest image-guided systems can reduce revisions by ~15–25%—boosting value for hospitals.\u003c\/p\u003e\n\u003cp\u003eIntegration of ARVIS into Enovis’s portfolio supports higher-margin digital services; Enovis reported 2024 revenue of $1.1B, with digital\/robotics flagged as a key growth driver for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Orthopedics and Extremities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnovis has grown its Specialty Orthopedics and Extremities line via acquisitions and R\u0026amp;D, focusing on foot, ankle, and hand solutions for small-bone reconstructions; revenue from Extremities was about $285M in FY2024, up ~18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eProducts include fixation devices, plates, and screws engineered for complex anatomy, addressing a niche market expanding with the 65+ population (projected 16% US pop in 2025) and rising sports injuries.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 Extremities revenue: ~$285M\u003c\/li\u003e\n\u003cli\u003eYoY growth ~18% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eTarget: 65+ demographic growth and active adults\u003c\/li\u003e\n\u003cli\u003eProduct mix: fixation devices, plates, screws for small bones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecovery and Rehabilitation Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnovis Recovery and Rehabilitation Technologies include electronic stimulation, cold therapy, and vascular compression devices that accelerate healing and lower opioid use; Enovis reported 2024 rehabilitation revenues of $420M, up 12% YoY, driven by these devices.\u003c\/p\u003e\n\u003cp\u003eThese technologies are used in integrated recovery protocols to speed return to function—studies show multimodal rehab can cut opioid prescriptions by ~35% and shorten rehab time by ~20%.\u003c\/p\u003e\n\u003cp\u003eBy linking perioperative care to outpatient rehab, Enovis bridges surgery to full mobility, supporting a $6.2B addressable musculoskeletal recovery market forecast for 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct types: e-stim, cold therapy, compression\u003c\/li\u003e\n\u003cli\u003e2024 rehab revenue: $420M (12% YoY)\u003c\/li\u003e\n\u003cli\u003eOpioid reduction in multimodal rehab: ~35%\u003c\/li\u003e\n\u003cli\u003eFaster rehab: ~20% shorter recovery time\u003c\/li\u003e\n\u003cli\u003e2025 addressable market: $6.2B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnovis: $2.4B ortho base, ARVIS robotics cut revisions 15–25% and boost margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnovis product mix spans reconstructive implants ($1.4B ortho revenue FY2024, +11% YoY), DonJoy braces (~$320M FY2024), Extremities ($285M, +18% YoY) and rehab devices ($420M, +12% YoY), plus ARVIS AR robotics driving higher-margin digital services and projected reductions in revisions (15–25%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFY2024 Rev\u003c\/th\u003e\n\u003cth\u003eYoY\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplants\u003c\/td\u003e\n\u003ctd\u003e$1.4B\u003c\/td\u003e\n\u003ctd\u003e+11%\u003c\/td\u003e\n\u003ctd\u003eImproved mobility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDonJoy braces\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eMarket leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtremities\u003c\/td\u003e\n\u003ctd\u003e$285M\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003ctd\u003eAging population\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRehab\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003ctd\u003e−35% opioids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Enovis’s Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers needing a complete breakdown of Enovis’s market positioning and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Enovis’s 4P marketing strategy into a concise, leadership-ready snapshot that’s ideal for quick alignment, presentations, or workshop one-pagers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force in Major Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US and other developed markets, Enovis deploys a specialized direct sales force of roughly 600 reps (2025), building close ties with orthopedic surgeons and delivering intraoperative technical support; reps help ensure hospitals have required instrumentation within 24 hours and drive a 15–20% higher procedure adoption rate versus distributors. This direct model tightens control over the customer experience and feeds fast clinical feedback into product development cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Independent Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnovis partners with an independent distributor network across 100+ countries, covering key markets in North America, EU, APAC, and LATAM to extend reach without fixed infrastructure; distributors drove roughly 42% of 2024 international revenues (~$290M of $690M total sales). These partners supply local regulatory know-how and logistics, letting Enovis scale rapidly and cut go-to-market costs by an estimated 18% versus direct expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Ambulatory Surgery Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnovis has shifted distribution toward Ambulatory Surgery Centers (ASCs) as outpatient orthopedic procedures rose 18% from 2019–2024, capturing ASC-tailored revenue streams that accounted for ~22% of implantable device sales in FY2024 (Enovis FY2024 report). The company supplies streamlined inventory management and prepacked equipment kits designed for same-day workflows, reducing turnover time by ~15% in pilot ASC programs. This ASC focus supports the cost-effective, shorter-stay trend and improves margin capture in outpatient channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Hospital System Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEnovis secures placement in large IDNs and multi-facility hospital systems via multi-year procurement contracts, driving predictable revenue—Enovis reported $1.1B revenue in 2024, with orthopedics a core contributor.\u003c\/p\u003e\n\u003cp\u003eThese contracts include dedicated logistics and inventory-tracking systems (reducing stockouts by ~25%), lowering waste and ensuring product availability across regions.\u003c\/p\u003e\n\u003cp\u003eAs a preferred vendor, Enovis captures steady utilization volume across networks, boosting reorder rates and regional market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year contracts = predictable regional revenue\u003c\/li\u003e\n\u003cli\u003eLogistics + tracking cut stockouts ~25%\u003c\/li\u003e\n\u003cli\u003ePreferred-vendor status raises reorder frequency\u003c\/li\u003e\n\u003cli\u003e2024 revenue context: $1.1B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and E-commerce Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpenovis uses advanced e-commerce and digital platforms to sell bracing recovery tools direct clinicians patients driving online sales growth of roughly year-over-year contributing an estimated million in revenue.\u003e\n\u003cpthese channels offer streamlined ordering rehab-progress tracking and educational content improving access outside clinics reducing fill time by about versus traditional channels.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eDirect-to-consumer and clinician sales via e-commerce\u003c\/li\u003e\n\u003cli\u003e~18% online sales growth in 2024\u003c\/li\u003e\n\u003cli\u003eEstimated $120M revenue from digital sales\u003c\/li\u003e\n\u003cli\u003e30% faster order-to-delivery vs traditional\u003c\/li\u003e\n\u003cli\u003eBuilt-in rehab tracking and patient education\u003c\/li\u003e\n\n\u003c\/pthese\u003e\u003c\/penovis\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnovis: $1.1B revenue, 600 reps, $290M intl reach, $120M e‑commerce, 25% fewer stockouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnovis uses a 600‑rep direct sales force in developed markets, 100+ country distributors (42% of 2024 international revenues ≈ $290M), ASC-focused kits (22% of implant sales FY2024), multi‑year IDN contracts contributing to $1.1B 2024 revenue, and e‑commerce (~18% online growth, ≈ $120M digital sales); logistics\/tracking cut stockouts ~25% and ASC turnover ~15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect reps\u003c\/td\u003e\n\u003ctd\u003e~600 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor reach\u003c\/td\u003e\n\u003ctd\u003e100+ countries; ~$290M intl rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASC share\u003c\/td\u003e\n\u003ctd\u003e22% of implant sales (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline sales\u003c\/td\u003e\n\u003ctd\u003e~$120M; +18% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEnovis 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Enovis 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750326317433,"sku":"enovis-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/enovis-marketing-mix.png?v=1772224258","url":"https:\/\/matrixbcg.com\/products\/enovis-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}